drugset
drugset / Trial / NCT01348919

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT01348919 ↗

Phase 1/2 Completed 11 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma.

Timeline

Start
2011-08-03
Primary completion
2013-03-14
Completion
2013-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject DELANZOMIB Small molecule — Intravenous
Background Dexamethasone Small molecule 40 mg Oral
Background Lenalidomide Other / unclassified 25 mg Oral

Indications

plasma cell myeloma